Skip to main content

Blood Purification for the Treatment of Pathogen Associated Shock

Active, not recruiting · Not applicable · NCT05011656

Conditions: Septic Shock

At a glance

Research payments reported, 2025
$154,966
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
15

About the trial

Sponsor
ExThera Medical Corporation (with Uniformed Services University of the Health Sciences)
Tested
Seraph-100 + State of the Art Care (device), State of the Art Care (device)
Dates
Started 2024-04-19; completion 2027-07-31
Results posted
Not yet

This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and older) admitted to the ICU with all of the following: • Pathogen associated shock defined as: * The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation * Presence of a pathogen detected in the bloodstream within 72 hours of screening using commercially available in-vitro diagnostic testing

From ClinicalTrials.gov, last updated 2026-04-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Exthera Medical Corporation reported $154,966 in research payments for this study in 2025 (5 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Institute of Ecmo Development LLC $131,143
  • Mayo Clinic $23,824

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.